Rheumatologic Disease
12
7
7
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Testimonials and Navigation in Rheumatology
A Study of SPY072 in Rheumatic Disease
EULAR Impact of Rheumatic and Musculoskeletal Diseases Survey
Psorcast Mobile Study
Rheumatology Diet Study
Greater Manchester CARDIOvascular Pathology in Immune-Mediated Inflammatory Diseases
A Clinical Study to Map the HLA Genomic Region in the Greek Population
Turkish Cultural Adaptation, Validity and Reliability of the "Gait Outcomes Assessment List"
Proof-of-concept Study of 'JIA Toolbox' for Children and Young People (CYP) With Juvenile Idiopathic Arthritis (JIA)
EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMAB
Prevalence and Factors of Sarcopenia and in Patients With Primary Sjogren's Syndrome
Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment